Literature DB >> 35554754

Usefulness of dual isotope 123I-IMP and 201Tl SPECT for the diagnosis of primary central nervous system lymphoma and glioblastoma.

Sho Osawa1, Masahiko Tosaka2, Keishi Horiguchi1, Azusa Tokue3, Tetsuya Higuchi3, Yoshito Tsushima3, Yuhei Yoshimoto1.   

Abstract

BACKGROUND: Preoperative differential diagnosis between primary central nervous system lymphoma (PCNSL) and glioblastoma (GBM) is important because these tumors require different surgical strategies. This study investigated the usefulness of dual isotope, iodine-123-labeled N-isopropyl-p-iodo-amphetamine (123I-IMP) and thallium-201 chloride single-photon emission computed tomography (201Tl SPECT) for the differential diagnosis.
METHODS: Twenty-five PCNSL patients and 27 GBM patients who underwent dual isotope imaging, 123I-IMP and 201Tl SPECT, are included. Tumor-to-normal (T/N) ratio was calculated from the ratio of maximum tracer counts in the lesion to the mean counts in the contralateral cerebral cortex. The mean and minimum apparent diffusion coefficient values (ADCmean and ADCmin, respectively) on magnetic resonance imaging were also analyzed.
RESULTS: Delayed phase 123I-IMP SPECT was the most useful imaging examination for the differentiation between PCNSL and GBM compared with early phase 123I-IMP SPECT, early and delayed phase 201Tl SPECT, ADCmean, and ADCmin. However, the median T/N ratios of PCNSL and GBM were 1.32 and 0.83, respectively, in the delayed phase 123I-IMP SPECT. On the other hand, the median T/N ratios of PCNSL and GBM were 3.10 and 2.34, respectively, in the delayed phase 201Tl SPECT, with excellent tumor detection.
CONCLUSION: Delayed phase 123I-IMP SPECT could differentiate between PCNSL and GBM with high accuracy, but T/N ratio was low and tumor detection was poor. 201Tl SPECT was useful for estimation of the malignancy and localization of the tumors with high T/N ratio. Dual isotope 123I-IMP and 201Tl SPECT was useful for the preoperative diagnosis of PCNSL and GBM.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  123I-IMP SPECT; 201Tl SPECT; ADC; Glioblastoma; Primary central nervous system lymphoma

Mesh:

Substances:

Year:  2022        PMID: 35554754     DOI: 10.1007/s10147-022-02171-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.850


  44 in total

1.  Differentiating Primary Central Nervous System Lymphomas From Glioblastomas and Inflammatory Demyelinating Pseudotumor Using Relative Minimum Apparent Diffusion Coefficients.

Authors:  Jian-Bo Wen; Wei-Yuan Huang; Wei-Xing-Zi Xu; Gang Wu; Dao-Ying Geng; Bo Yin
Journal:  J Comput Assist Tomogr       Date:  2017 Nov/Dec       Impact factor: 1.826

2.  Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.

Authors:  Christopher P Fox; Elizabeth H Phillips; Jeffery Smith; Kim Linton; Eve Gallop-Evans; Claire Hemmaway; Dorothee P Auer; Charlotte Fuller; Andrew J Davies; Pamela McKay; Kate Cwynarski
Journal:  Br J Haematol       Date:  2018-11-23       Impact factor: 6.998

3.  An extent of resection threshold for newly diagnosed glioblastomas.

Authors:  Nader Sanai; Mei-Yin Polley; Michael W McDermott; Andrew T Parsa; Mitchel S Berger
Journal:  J Neurosurg       Date:  2011-03-18       Impact factor: 5.115

4.  Can the standardized uptake value characterize primary brain tumors on FDG-PET?

Authors:  R Hustinx; R J Smith; F Benard; A Bhatnagar; A Alavi
Journal:  Eur J Nucl Med       Date:  1999-11

5.  Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.

Authors:  Keishi Makino; Toshinori Hirai; Hideo Nakamura; Ryuji Murakami; Mika Kitajima; Yoshinori Shigematsu; Rumi Nakashima; Shinya Shiraishi; Hiroyuki Uetani; Koya Iwashita; Masuma Akter; Yasuyuki Yamashita; Jun-ichi Kuratsu
Journal:  Ann Nucl Med       Date:  2011-03-16       Impact factor: 2.668

6.  Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography.

Authors:  Koji Yamashita; Takashi Yoshiura; Akio Hiwatashi; Osamu Togao; Koji Yoshimoto; Satoshi O Suzuki; Koichiro Abe; Kazufumi Kikuchi; Yasuhiro Maruoka; Masahiro Mizoguchi; Toru Iwaki; Hiroshi Honda
Journal:  Neuroradiology       Date:  2012-09-09       Impact factor: 2.804

7.  The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.

Authors:  Shigeru Yamaguchi; Kenji Hirata; Hiroyuki Kobayashi; Tohru Shiga; Osamu Manabe; Kentaro Kobayashi; Hiroaki Motegi; Shunsuke Terasaka; Kiyohiro Houkin
Journal:  Ann Nucl Med       Date:  2014-04-18       Impact factor: 2.668

8.  Carbon-11-methionine and fluorine-18-FDG PET study in brain hematoma.

Authors:  S Dethy; S Goldman; S Blecic; A Luxen; M Levivier; J Hildebrand
Journal:  J Nucl Med       Date:  1994-07       Impact factor: 10.057

9.  Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.

Authors:  X Lin; M Lee; O Buck; K M Woo; Z Zhang; V Hatzoglou; A Omuro; J Arevalo-Perez; A A Thomas; J Huse; K Peck; A I Holodny; R J Young
Journal:  AJNR Am J Neuroradiol       Date:  2016-12-08       Impact factor: 3.825

10.  Differentiation between primary cerebral lymphoma and glioblastoma using the apparent diffusion coefficient: comparison of three different ROI methods.

Authors:  Sung Jun Ahn; Hyun Joo Shin; Jong-Hee Chang; Seung-Koo Lee
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.